Wave Life Sciences’ WVE-007 obesity candidate delivered mixed early clinical data and sent the company’s shares down sharply. In the Phase I INLIGHT trial (NCT06842186), the 240 mg cohort showed placebo-adjusted changes of less than 1% reduction in body weight at six months and a 3.3% decline in waist circumference—numbers investors viewed as short of expectations. The reporting also highlighted the benchmark Wave must reach for meaningful obesity efficacy: an FDA draft guidance target of at least a 5% mean percentage body weight reduction versus placebo at one year. Analysts cited in the coverage said the near-term value of INHBE/obesity looks limited pending later Phase IIa results. Wave’s next catalysts will be dose-response interpretation and Phase IIa efficacy expansion to clarify whether the mechanism can achieve clinically durable weight outcomes in a larger, more representative population.